Sanofi to Acquire Blueprint Medicines for $9.1 Billion
French pharmaceutical giant Sanofi has announced a major acquisition of U.S.-based biotech firm Blueprint Medicines in a deal worth $9.1 billion in cash, with an additional $400 million tied to milestone payments, bringing the total potential value to $9.5 billion. The move is aimed at strengthening Sanofi’s presence in the immunology and rare diseases space, areas that are central to its growth strategy.
Blueprint’s flagship asset, Ayvakit (avapritinib), is the sole FDA-approved product for advanced systemic mastocytosis—a life-threatening and usually debilitating immune cell disorder. Alone in Q1 2025, Ayvakit posted $150 million in sales, and projected annual revenues were predicted to hit $720 million and as much as $2 billion by 2030.
Sanofi will make a cash payment of $129.00 per share, which is a 23% premium to Blueprint’s latest share price. The news of the acquisition led to a 26% intraday rise in Blueprint shares. Sanofi CEO Paul Hudson stated that the acquisition fits with the company’s aim to enhance its pipeline of innovative medicines, particularly as it tries to diversify its dependence on its top-selling drug Dupixent.
The acquisition follows a wave of consolidation among biotech companies, with large pharma increasingly looking at smaller, niche players to bolster their R&D pipelines. Even though it has suffered recent disappointments in its own drug development pipeline, Sanofi continues to make heavy investments in high-impact areas. The acquisition of Blueprint represents an important step in that direction, reinforcing its position in the rare disease and immunology franchises.
